Overall survival data from CheckMate-069, a phase II trial of a Opdivo and Yervoy combination regimen in patients with previously untreated advanced melanoma, demonstrated a two-year overall survival rate of 69 percent compared to 53 percent for Yervoy alone (HR=0.58 [95% CI: 0.31-1.08]) in patients with BRAF wild-type advanced melanoma.
A phase III trial of farletuzumab failed to meet its endpoints of significantly increasing progression-free survival or overall survival in ovarian cancer patients.
A phase III trial of PD-1 inhibitor Opdivo showed significant survival benefit at one year—compared to investigator's choice of methotrexate, docetaxel or cetuximab—in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
FDA approved Gilotrif (afatinib) tablets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed after treatment with platinum-based chemotherapy.
The University of Chicago and AbbVie entered into a five-year collaboration in oncology. Initially, both organizations will work together to advance research in several areas of oncology, which could include, among others, breast, lung, prostate, colorectal and hematological cancer. Research projects are chosen by a joint steering committee, comprised of representatives from each organization. AbbVie... […]
NIH has suspended the facilities that produce investigational compounds for an NCI laboratory engaged in cell therapy production and a National Institute of Mental Health facility producing positron emission tomography materials.
The NCI Board of Scientific Advisors approved a proposal to expand the infrastructure and capacity of the SEER program, including introducing registries designed specifically to support cancer research projects, an increase of the program's overall budget, and moving toward a more advanced, uniform data management system.
The American Academy of Arts and Sciences elected 213 new members, including some of the world's most accomplished scholars, scientists, writers, artists, as well as civic, business, and philanthropic leaders.
NANCY DAVIDSON was inaugurated as president of the American Association for Cancer Research for 2016-2017 at the association's annual meeting in New Orleans.
ROBERT WEINBERG was honored for his contributions to cancer research and cancer biology with the 13th annual AACR Award for Lifetime Achievement in Cancer Research. Weinberg is a founding member of the Whitehead Institute for Biomedical Research; the Daniel K. Ludwig professor for cancer research in the Department of Biology at the Massachusetts Institute of... […]
